Table 2.
Risk factors associated with regimen switching away from an integrase-inhibitor (INSTI)-based regimen
| Treatment switches Number of patients |
Person-years (pys) |
Rate (per 100 pys) |
95% CI | HR | Multivariate 95% CI |
P | ||
|---|---|---|---|---|---|---|---|---|
| Total | 598 | 60 | 1274.0 | 4.7 | 3.7, 6.1 | |||
| Age at INSTI initiation (years) | 0.896 | |||||||
| ≤30 | 9 | 1 | 14.9 | 6.7 | 1.0, 47.6 | 0.80 | 0.10, 6.65 | 0.834 |
| 31–40 | 61 | 5 | 107.3 | 4.7 | 1.9, 11.2 | 1 | ||
| 41–50 | 231 | 24 | 495.0 | 4.9 | 3.3, 7.2 | 1.18 | 0.47, 2.95 | 0.722 |
| 51+ | 297 | 30 | 656.9 | 4.6 | 3.2, 6.5 | 1.10 | 0.43, 2.84 | 0.842 |
| Gender | ||||||||
| Male | 566 | 53 | 1212.6 | 4.4 | 3.3, 5.7 | 1 | ||
| Female | 32 | 7 | 61.5 | 11.4 | 5.4, 23.9 | 2.53 | 1.10, 5.82 | 0.029 |
| HBV surface antigen Co-infection | ||||||||
| Negative/not tested | 575 | 58 | 1221.9 | 4.8 | 3.7, 6.1 | 1 | ||
| Positive | 23 | 2 | 52.2 | 3.8 | 1.0, 15.3 | 1.03 | 0.48, 2.22 | 0.942 |
| HCV antibody co-infection | ||||||||
| Negative/not tested | 524 | 52 | 1120.9 | 4.6 | 3.5, 6.1 | 1 | ||
| Positive | 74 | 8 | 153.1 | 5.2 | 2.6, 10.5 | 1.05 | 0.27, 4.11 | 0.941 |
| Previous time on ART | ||||||||
| Per year | 1.01 | 0.94, 1.07 | 0.844 | |||||
| Patient experience | ||||||||
| Second-line | 199 | 20 | 382.1 | 5.2 | 3.4, 8.1 | 1 | ||
| Highly experienced | 399 | 40 | 891.9 | 4.5 | 3.3, 6.1 | 0.79 | 0.39, 1.58 | 0.500 |
| Viral load at INSTI initiation | ||||||||
| Failure (>50 copies/mL) | 190 | 19 | 437.1 | 4.4 | 2.8, 6.8 | 1 | ||
| Suppressed (≤50 copies/mL) | 311 | 39 | 649.0 | 6.0 | 4.4, 8.2 | 1.30 | 0.75, 2.28 | 0.351 |
| Missing | 97 | 2 | 187.9 | 1.1 | 0.3, 4.3 | |||
Global P-value for the age at INSTI initiation is a test for trend.
pys, person years; CI, confidence interval; HR, hazard ratio; HBV, hepatitis B virus co-infection; HCV, hepatitis C virus co-infection; ART, antiretroviral therapy